CD4 and prostate cancer: Mechanistic studies showed that the immunodominant PSMA459 epitope becomes cysteinylated under normal physiologic conditions, and this cysteinylated form of PSMA459 inhibits the CD4+ T cell recognition of prostate cancer cells.